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Abstract
The development of and adherence to quality indicators in gastroenterology, as in all of medicine, 
is increasing in importance to ensure that patients receive consistent high-quality care. In addition, 
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government-based and private insurers will be expecting documentation of the parameters by 
which we measure quality, which will likely affect reimbursements. Barrett’s esophagus remains a 
particularly important disease entity for which we should maintain up-to-date guidelines, given its 
commonality, potentially lethal outcomes, and controversies regarding screening and surveillance. 
To achieve this goal, a relatively large group of international experts was assembled and, using the 
modified Delphi method, evaluated the validity of multiple candidate quality indicators for the 
diagnosis and management of Barrett’s esophagus. Several candidate quality indicators achieved 
>80% agreement. These statements are intended to serve as a consensus on candidate quality 
indicators for those who treat patients with Barrett’s esophagus.
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Barrett’s esophagus (BE) is a condition in which normal squamous mucosa lining the distal 
esophagus is replaced with metaplastic intestinal-type columnar epithelium.1 The prevalence 
of BE among the general population in the United States is estimated at 5.6%, and occurs 
predominantly in white men aged >50 years.2,3 BE is strongly associated with 
gastroesophageal reflux disease and with a considerably increased risk for development of 
esophageal adenocarcinoma (EAC), which is estimated to be at least 10 times more 
prevalent in people with BE than in the general population.4,5 BE is the only known 
precursor to EAC, and it can progress from metaplastic to low-grade dysplasia (LGD), and 
from there to high-grade dysplasia (HGD) and ultimately to EAC.6 Although the progression 
from BE to EAC is estimated to be <0.5%,7,8 when EAC is diagnosed in symptomatic 
patients, the 5-year survival is <3%.9 Early detection and treatment of BE is essential to halt 
its progression and impact the incidence of EAC, which has grown 6-fold in the last 30 
years.9 Guidelines generally recommend surveillance endoscopy in people with BE to detect 
and treat neoplasia and early signs of HGD in order to prevent the development of EAC.1
Recent technological advances in endoscopic imaging and treatment modalities have spurred 
greater interest in the detection and treatment of BE and its sequelae. There are also 
increased studies aimed at determining specific risk factors to guide physicians in screening 
and surveillance. As a result, the major gastrointestinal societies in the United States and the 
United Kingdom have issued updated guidelines recently.1,10
Although there is consensus on the importance of BE and the potential need for screening 
and surveillance, there are a variety of opinions on the specific means by which this should 
be accomplished. For example, in order to detect early neoplasia, neoplastic lesions can be 
small, difficult to visualize endoscopically, and might not be detected by random quadrant 
biopsies, making some investigators strong proponents of routine use of advanced imaging 
methods, such as chromoendoscopy or electronic chromoendoscopy; others disagree.1 
Similarly, there is little agreement on which landmarks and classification system should be 
consistently recorded during endoscopy in BE patients to demonstrate a high-quality 
Sharma et al. Page 2













examination; whether medical treatment for BE should be aggressive and include high doses 
of proton pump inhibitors, statins, and/or aspirin; and whether symptom resolution alone 
should be the end point of treatment. The proper intervals for surveillance are also 
controversial, with a broad range of opinions and many recommendations supported by low-
grade evidence at best. Furthermore, in this era of cost containment, BE represents a 
conundrum to the public, as it can lead to lethal consequences, but the economic and health 
care costs required to prevent death are formidable.11
Consequently, there is an important need to identify valid quality indicators for standardize 
high-quality care in BE by adherence to defined criteria. The Centers for Medicare and 
Medicaid Services and private payers will increasingly demand documentation of quality 
measures through participation in voluntary reporting programs, such as the Physician 
Quality Reporting System to receive payment incentives and at some point in the future 
reimbursement will likely be contingent on adherence to validated quality indicators, once 
they are defined.12
To address this need, the American Gastroenterological Association conducted a state-of-the 
art meeting of experts in BE. During the meeting, one of the goals was to establish a 
consensus on the description of the pathophysiology, management, and goals of treatment 
for patients with BE, and develop a set of candidate quality indicators and best practice 
advisors for gastroenterologists to follow and document.
Methods
Development of Candidate Quality Indicator Statements
In August 2013, a group of 25 international experts on BE were approached and agreed to 
serve as faculty for the consensus conference and to draft a set of potential quality indicator 
statements based on the medical literature. This was based on the domains of diagnosis/
screening, surveillance, treatment and management of barrett’s and early cancer. The 
approval of each statement was ultimately achieved through a series of electronic and in-
person discussions using the modified Delphi method.13–15 An initial group of core faculty 
members was created and agreed to draft these statements. Each faculty member was 
assigned 4 subfaculty members who approved or disapproved of each statement. Not all 
faculty members had access to the complete list of references during this process.
Voting on Candidate Quality Indicator Statements
All statements underwent vigorous edits throughout the entire process. Once vetted by the 
subfaculty, each statement was sent electronically to the entire group for a vote to determine 
whether or not the statement should be considered as a candidate quality indicator. 
Specifically, those statements that were approved by 80% of voters went on to a second 
round of discussion, after which participants voted on agreement of the actual meaning of 
the statement. For this part of the voting, each faculty had the following options for voting 
on the statements: (1) strong agree; (2) agree; (3) disagree; (4) strongly disagree, or (5) 
neither agree nor disagree. Statements not approved in the second round of voting were 
edited based on input from faculty and resubmitted for another round of voting. In August 
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2013, the group met for a face-to-face discussion of statements that still failed to meet with 
80% approval (ie, agreement), despite 3 rounds of voting. During this final face-to-face 
meeting, after a prolonged discussion on the statements not yet meeting the predefined 80% 
acceptance, a final round of voting was conducted anonymously.
Grading of Recommendations Assessment, Development and Evaluation Methodology for 
the Quality Indicator Statements
The quality of evidence was rated using the Grading of Recommendations Assessment, 
Development and Evaluation criteria (high, moderate, low, or very low) using the approach 
developed by the Grading of Recommendations Assessment, Development and Evaluation 
working group established in 2000 (Tables 1–4).16,17
Results
The following statements were approved to serve as the basis for our consensus conference 
titled “Candidate Quality Indicators for the Diagnosis, Treatment and Management of 
Patients With BE.”
Screening, Diagnosis, and Staging
Statement 1: For patients in whom BE is being considered, the squamo-columnar 
junction, the gastroesophageal junction (GEJ), and the location of the diaphragmatic 
hiatus (if there is a hiatal hernia present) should be recorded on each upper endoscopy. 
Agreement: 20 of 23 = 87% (35% strongly agree, 52% agree, 8.6% neither, 4.3% disagree. 
Grade of recommendation: weak. Quality of evidence: moderate.
Discussion
These important landmarks help standardize effective documentation of the presence and 
extent of columnar-lined epithelium in relation to the GEJ and hiatal hernia during upper 
endoscopy. Detection of these landmarks has been found to have high inter- and intra-
observer agreement.18,19 Furthermore, the recognition of these landmarks is key if a 
diagnosis of BE is being considered. In the absence of documentation of these landmarks, 
the diagnosis of BE may be suspect, and a patient without BE might be given an incorrect 
diagnosis with subsequent economic, testing, and anxiety-producing sequelae. The best 
description of the endoscopic location of the GEJ, supported by an international Barrett’s 
working committee was “the proximal limit of linear gastric mucosal folds in routine 
diagnostic endoscopic practice.” “The proximal limit of gastric mucosal folds is defined best 
as the most proximal point at which there is any evidence of a linear fold of gastric mucosa 
which is best visualized when the esophagus is distended minimally to the point that the 
proximal ends of the gastric folds appear.”18
Statement 2: If BE is suspected on an endoscopy, the endoscopist should document the 
extent of suspected BE using Prague criteria. Agreement: 19 of 23 = 82.6% (43% 
Strongly Agree, 39% Agree, 13% neither, 4.3% disagree. Grade of recommendation: weak. 
Quality of evidence: moderate.
Sharma et al. Page 4














The length of BE can be highly variable among patients and, in the absence of a 
standardized classification system, reporting can be subject to poor inter-observer 
agreement. In addition, BE length has been found to be an important factor in both the risk 
of progression and the number of sessions required to treat endoscopically. Traditional 
methods of measurement have only accounted for maximum BE length, which might not be 
an accurate indicator of total surface area, given the wide variation in squamo-columnar 
junction contour. Measurement of BE length using the Prague criteria, which takes into 
account both circumferential and maximal length to provide a C and M score has been found 
to have a high inter-observer agreement by both experts and medical trainees and by both 
Western and Asian endoscopists.18 As a result, it is considered the preferred system for the 
measurement of BE extent.
Statement 3: The normal-appearing and normally located squamo-columnar junction 
should not be biopsied. Agreement: 19 of 22 = 86.3% (68.1% strongly agree, 18.2% agree, 
4.5% neither, 4.5% disagree, 4.5% strongly disagree). Grade of recommendation: strong. 
Quality of evidence: moderate.
Discussion
When biopsies obtained from normally appearing and located squamo-columnar junction 
demonstrate intestinal metaplasia, it probably represents intestinal metaplasia of cardia, a 
different clinical entity from BE. Intestinal metaplasia of the cardia is associated with 
Helicobacter pylori infection and older age, while BE is associated with gastroesophageal 
reflux disease. The malignant potential of intestinal metaplasia of cardia is not entirely clear, 
but studies to date indicate that it has an extremely low risk of progression to cancer.20–24
Sharma et al20 prospectively evaluated the risk of dysplasia in 177 patients with short 
segment Barrett’s esophagus (SSBE) and cardia intestinal metaplasia (n = 76). Dysplasia 
prevalence was significantly higher in patients with SSBE compared with those with cardia 
intestinal metaplasia (11.3% vs 1.3%; P = .0058). When patients with SSBE (n = 78) and 
cardia intestinal metaplasia (n = 34) were followed for a mean of 31 months (range, 8 – 100 
months) and 24 months (range, 6 – 80 months), respectively, 9 patients with SSBE 
developed dysplasia (7 LGD and 2 HGD), while only 1 patient with cardia intestinal 
metaplasia developed dysplasia. The time to dysplasia development was significantly longer 
in patients with cardia intestinal metaplasia (P = .0077 per log-rank test). While 1 patient 
with HGD in a patient with SSBE progressed to adenocarcinoma, LGD was not detected on 
repeat endoscopy in the patient with cardia intestinal metaplasia 1 year later.20
Similarly, in a population-based cohort study in 2011 by Jung et al,24 487 patients (401 with 
BE and 86 with intestinal metaplasia from normal or “irregularly”-appearing squamo-
columnar junction) were identified in Minnesota and followed for a median interval of 7 
years (BE) or 8 years (intestinal metaplasia at the GEJ). Of 355 patients in BE group with no 
prevalent HGD/EAC, in 12 months, 18 progressed to dysplasia (10 from no dysplasia to 
HGD, 6 from no dysplasia to HGD, and 2 from LGD to HGD). Of 55 (64%) patients with 
intestinal metaplasia at the GEJ who underwent at least 1 subsequent endoscopy, LGD that 
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was detected in 6 patients on first endoscopy was not found on subsequent endoscopies and 
none of these patients progressed to EAC.24 Based on these findings, the experts agreed that 
this quality indicator will reduce the incorrect labeling of a patient with BE and 
subsequently reduce any future surveillance if contemplated.
Surveillance
Statement 4: If systematic surveillance biopsies performed in a patient known to have 
BE show no evidence of dysplasia, follow-up surveillance endoscopy should be 
recommended no sooner than 3 to 5 years. Agreement: 21 of 23 = 91.3% (17.3% strongly 
agree, 74% agree, 8.6% neither). Grade of recommendation: weak. Quality of evidence: low.
Discussion
Given the weak recommendation and low quality of evidence, this recommendation should 
be guided by additional discussion of the general risks and benefits of surveillance with the 
patient as there are no randomized controlled trials or other definitive data showing a 
survival advantage of surveillance endoscopy in BE patients. Nevertheless, several 
retrospective studies have shown that EAC was diagnosed at an earlier stage in BE patients 
enrolled in surveillance programs when compared with patients not surveyed.25–28 However, 
the survival benefit for patients with EAC who have participated in surveillance is not clear 
yet due to the limitations of performing a similar prospective study.26–29
Nondysplastic Barrett’s esophagus (NDBE) is known to progress to EAC at the rate of 
0.12% – 0.59% per year based on evidence from several published studies.4,30–32 In a 
prospective, multicenter outcomes project (n = 1204), the mean time of progression from 
NDBE to EAC was calculated at 5.29 years (SD 3.83 years; range, 1.05 – 15.3 years). A 
cost-effectiveness analysis showed that surveillance every 5 years was the only effective 
strategy for NDBE surveillance.30 Experts agreed that, in accordance with current American 
Gastroenterological Association guidelines, in patients with known NDBE, follow-up 
surveillance endoscopy should be recommended every 3 to 5 years. However, there was also 
general discussion regarding limited data pertaining to the effectiveness of surveillance and 
much fewer data on appropriate surveillance interval. The aim of this measure is actually to 
reduce unnecessary and frequent endoscopy that is performed in patients with NDBE and to 
ensure appropriate discussion of risk and benefit with the patient.
It was also noted that current research is focusing on more clearly identifying factors in 
Barrett’s patients that predict a higher likelihood of developing cancer; these patients 
therefore might benefit from a surveillance program. Data from these ongoing studies are 
not robust yet to propose a strong recommendation.
Statement 5: If a patient with known BE undergoes surveillance endoscopy, systematic 
biopsies should be taken from every 1 to 2 cm in 4 quadrants throughout the extent of 
the endoscopically involved segment. Agreement: 22 of 23 = 95.7% (52.1% strongly agree, 
43.4% agree, 4.3% neither). Grade of recommendation: strong. Quality of evidence: 
moderate.
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Reliable demonstration of the presence of intestinal metaplasia and/or dysplasia from biopsy 
specimens of the distal esophagus in patients with BE is associated with significant sampling 
errors. The use of a systematic biopsy protocol, specifically 4-quadrant biopsies every 1 to 2 
cm (ie, Seattle protocol), remains a necessary component of endoscopic surveillance of BE. 
In a retrospective study, Abrams et al33 evaluated 2245 BE surveillance cases for adherence 
to biopsy guidelines. The odds of detecting dysplasia significantly decreased with 
nonadherence to a systematic biopsy protocol (odds ratio = 0.53; 95% confidence interval: 
0.35 – 0.82). Theoretically, this also applies to detecting intestinal metaplasia in a field of 
non–goblet cell columnar epithelium. Notably, however, even complete adherence to the 
Seattle protocol33 (4 quadrant biopsies every 2 cm) does not eliminate sampling errors, 
underscoring the limitations of histologic sampling of only a relatively small proportion of 
the visible columnar mucosa in the esophagus. This limitation underscores the need to 
continue to develop endoscopic surveillance techniques that can more comprehensively and 
expeditiously scan Barrett’s mucosa for dysplasia without sole dependence on random 
biopsies.
Statement 6: If a patient with known BE undergoes surveillance endoscopy, biopsies 
from any visible raised or depressed lesions should be obtained and processed 
separately from the systematic biopsies. Agreement: 22 of 23 = 95.7% (65.2% strongly 
agree, 30.4% agree, 4.3% neither). Grade of recommendation: strong. Quality of evidence: 
moderate.
Discussion
Endoscopically visible lesions within the BE segment, such as nodules,34 ulcers,35 
depressions, and areas of abnormal surface patterns, are more likely to harbor dysplasia and 
early neoplasia.36–40 In addition, data on endoscopic mucosal resection of these lesions have 
revealed a substantial rate of disease upstaging. As a result, these areas need to be 
documented, biopsied, and processed in such a manner as to allow accurate matching of the 
pathology of the area, as well as future identification of its location in the event that 
endoscopic therapy and/or closer monitoring is required.
Treatment and Management of Barrett’s Esophagus and Early Cancer
Statement 7: In patients with dysplastic BE or early EAC, a diagnostic endoscopic 
resection should be performed on any raised or suspicious areas. Agreement: 22 of 23 = 
95.6% (65.2% strongly agree, 30.4% agree, 4.3% neither). Grade of recommendation: 
strong. Quality of evidence: moderate.
Discussion
Experts agreed that staging or diagnostic endoscopic mucosal resection (EMR) should be 
performed in patients with dysplastic BE or early EAC, as findings on the resection 
specimen may demonstrate an under- or overestimation of the degree of neoplasia compared 
with findings on biopsies, as well as endoscopic ultrasound evaluation in up to 20% – 30% 
of patients. This is based on evidence from several studies. In 2005, Larghi et al41 
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prospectively enrolled 48 consecutive patients with biopsy-proven HGD or T1m EAC with 
nodular lesions <2 cm to evaluate the utility of EMR as a staging tool compared with 
endoscopic ultrasound. Eight of 48 patients had submucosal cancer on endoscopic 
ultrasound and underwent esophagectomy. In the other 40 patients (HGD, n = 25; EAC, n = 
15), EMR confirmed HGD in 19 of 25 patients, while the other 6 were found to have 
adenocarcinoma invading the lamina propria. In the other 15 patients found to have T1m 
EAC on biopsy specimens and endoscopic ultrasound, 6 were found to have submucosal 
invasion. In addition, it has been shown that submucosa and muscularis mucosa were present 
on histopathology in the majority of EMR specimens (99% vs 1.0% of biopsy specimens), 
which is critical to accurately staging BE-associated neoplasia.42 Similarly, several other 
studies have shown the utility of EMR as a staging tool in dysplastic BE or early esophageal 
cancer.36–40
Statement 8: In patients with BE-associated neoplasia, the goal of endoscopic 
treatment should be complete eradication of the BE segment in addition to any 
dysplastic lesions. Agreement: 23 of 23 = 100% (65.2% strongly agree, 34.8% agree). 
Grade of recommendation: strong. Quality of evidence: moderate.
Discussion
Manner et al43 enrolled 63 patients who underwent endoscopic mucosal resections to treat 
focal BE-associated HGD or intramucosal adenocarcinoma and randomized these patients to 
either surveillance (n = 30) or assigned them to undergo ablation of residual BE with argon 
plasma coagulation (APC) (n = 33). The follow-up duration was similar among patients in 
the APC (28.2 ± 13.7 months) and surveillance groups (24.7 ± 14.8 months; P = .159). 
However, patients in the APC group had a significantly lower number of secondary lesions 
(n = 1 [3%]) compared with those in the surveillance group (n = 11 [36.7%]) and, therefore, 
significantly higher recurrence-free survival in patients who underwent APC ablation of the 
residual BE (P = .005).43 Similarly, other studies showed a high rate of metachronous 
lesions in the BE segment in patients treated with endoscopic eradication therapies if 
residual BE persists.44 Based on the evidence from these studies, experts agreed that if the 
entire BE segment is not treated, the rate of cancer recurrence is high.
Overall Discussion: Candidate Quality Measures in Barrett’s Esophagus 
and International Consensus
Diagnosis and treatment of BE remains a challenge. First, as larger populations of BE 
patients are studied, the incidence of EAC arising from BE appears to be lower than 
previously thought.45 Second, neither clinical characteristics nor tissue markers reliably 
predict the development of cancer in these patients; we are, in effect, looking for a needle in 
a haystack. Third, cost-effectiveness analyses suggest that the number of BE patients needed 
to follow and treat to achieve a clear benefit is costly, beyond the usual standards of what is 
considered cost-effective.46–48 Fourth, without better predictive factors of cancer risk, it 
would be difficult and extremely costly to perform a prospective study evaluating the effects 
of screening, surveillance, and treatment, given the numbers of patients needed to follow. As 
a result, it is more important than ever to use experts in the field to achieve consensus 
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utilizing data from small clinical trials and numerous observational studies regarding the 
essentials of BE management in the absence of large clinical trials. Finally, there are no 
published data on quality measure in BE patients.
The Delphi process is one in which a series of statements or questions are discussed by 
experts in several rounds.13–15 After the first round, a leader summarizes the discussion 
without identifying the content of specific discussants. The experts are then asked to 
consider these points from colleagues and discuss and revise base questions and arrive at the 
best answer. Through a careful and thorough review of the literature and utilization of this 
approach, the selected committee of American Gastroenterological Association faculty and 
subfaculty were able to create a list of possible candidate quality indicators and clinical 
actions. Then, by a systematic process of evaluation, discussion, and vetting, the experts 
arrived at a consensus on the several statements described previously. These 8 measures 
discussed in detail can be considered as the basis for quality indicators and best practice 
advisors in the management of patients with BE, and serve as a template for physicians in 
documenting their quality of care for these patients. Conversely, several essential core 
questions had low-quality evidence or could not be agreed upon (table) and further data 
and/or discussion will be needed to provide answers. It should be noted, however, that a 
potential limitation of this method is that not all faculty had the complete list of references 
during this process.
The benefits of establishing such statements have further important implications in modern 
society. The Centers for Medicare and Medicaid Services are increasingly encouraging 
physicians to document quality measures by participating in voluntary reporting programs, 
such as the Physician Quality Reporting System, which provides incentives to physicians 
who report data on quality measures.12 Failure to participate in these programs can result in 
annual payment cuts. Physician reimbursement rates will be increasingly based on outcome 
measures performance as determined by the Centers for Medicare and Medicaid Services. It 
is therefore imperative to develop meaningful quality indicators that will provide invaluable 
information to practicing clinicians to provide quality care.
In summary, these guidelines put forth a group of candidate quality indicators agreed upon 
by experts in the field using the Delphi process. It is hoped that these candidate quality 
indicators will provide a background on which to base current care of patients with 
suspected or documented BE. Just as importantly, this process identified several fundamental 
questions in this field on which we could not agree and which require more data.
Abbreviations used in this paper
APC argon plasma coagulation
BE Barrett’s esophagus
EAC esophageal adenocarcinoma
EMR endoscopic mucosal resection
GEJ gastroesophageal junction
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NDBE nondysplastic Barrett’s esophagus
SSBE short segment Barrett’s esophagus
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Table 1
Definitions of the Quality of Evidence17
Quality of evidence Current definition Previous definition
High Very confident that the true effect lies close to the estimate of 
the effect
Further research is very unlikely to change our 
confidence in the estimate of effect
Moderate Moderately confident in effect estimate. The true effect may be 
close to the estimate of effect but there is a possibility that it 
may be substantially different
Further research is likely to have an important impact 
on our confidence in the estimate
Low Limited confidence in effect estimate. The true effect may be 
substantially different from the estimate of the effect
Further research is very likely to have an important 
impact on our confidence in the estimate of effect and 
is likely to change the estimate
Very low Very little confidence in effect estimate. True effect is likely to 
be substantially different from the estimate of effect
Any estimate of effect is very uncertain
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Table 2
Grading the Quality of Evidence16,17
Type of evidence Quality Decrease grade if: Increase grade if:
Randomized trial High Quality limitation Effect size
Observational study Low  Serious (−1)  Large (+1)
Any other study Very low  Very serious (−2)  Very large (+2)
Inconsistency If evidence of a dose response (+1)
 Serious (−1) Strength of association
 Very serious (−2)  Strong (RR >2 from 2 or more observational studies and no plausible 
confounding factors (+1)
Indirectness
 Serious (−1)  Very strong (RR >5 based on direct evidence and no confounding factors)
 Very serious (−2)
Imprecise or sparse data
 Serious (−1)
 Very serious (−2)
Publication bias
 Serious (1)
 Very serious (−2)
RR, relative risk.
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Table 3
Statements With ≥80% Consensus Agreement but Generally Low-Quality Evidence
If BE is suspected on an endoscopic screening examination, the endoscopist should obtain multiple systematic biopsies from the suspected 
segment. (Agreement 92%, strongly agree 57%, agree 35%, neither 4%, disagree 4%).
If a patient who is fit for endoscopy is diagnosed with BE as documented by the presence of intestinal metaplasia on histology of biopsies 
obtained from the tubular esophagus, enrollment in a surveillance endoscopy program should be strongly considered. (Agreement 92%, strongly 
agree 35%, agree 57%, neither 8%).
Patients undergoing surveillance biopsies for BE should be on an adequate dose of proton pump inhibitors to control reflux symptoms and 
erosive esophagitis. (Agreement 91%, strongly agree 61%, agree 30%, neither 9%).
In patients with BE undergoing endoscopic therapy, endoscopic resection of more than two-thirds of the circumference is not generally 
recommended due to the risk of stricture. (Agreement 83%, strongly agree 13%, agree 70%, neither 17%).
Radiofrequency ablation is an acceptable treatment option for BE patients with flat mucosa containing HGD without any visible lesions 
confirmed by high-resolution, high-definition endoscopy. (Agreement 87%, strongly agree 35%, agree 52%, neither 13%).
In patients who have completed endoscopic eradication of HGD and/or T1a EAC, follow-up endoscopic surveillance should be performed at 3, 
6, 12, 18, and 24 months and yearly thereafter. (Agreement 87%, strongly agree 26%, agree 61%, neither 13%).
In patients who have completed endoscopic eradication of HGD and/or T1a EAC, endoscopic surveillance should include targeted biopsies of 
any visible lesions along with random biopsies of the neosquamous mucosa. (Agreement 96%, strongly agree 52%, agree 44%, neither 4%).
Patients with EAC and no distant metastases on radiologic evaluation should undergo staging evaluation with endoscopic ultrasonography at the 
time of diagnosis (Agreement 87%, strongly agree 26%, agree 61%, neither 13%).
In patients with severe dysphagia from metastatic EAC, insertion of a self-expanding metal stent is the treatment of choice for symptom 
palliation. (Agreement 87%, strongly agree 26%, agree 61%, neither 13%).
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Table 4
Statements With <80% Consensus Agreement
Patients diagnosed with BE with without dysplasia should undergo a follow-up endoscopy within 1 year of first being diagnosed with BE to 
ensure the absence of prevalent dysplasia. (Agreement 72.0%, neither 34.8%, disagree 4.3%)
In patients with moderately or well-differentiated adenocarcinoma invading the mucosa without any lymph/vascular invasion, endoscopic 
resection is a valid alternative to surgery. (Agreement 73.9%, neither 21.7%, disagree 4.3%)
In patients with unresectable EAC complicated by esophageal stricture with esophagorespiratory fistulas, placement of a covered metal stent is 
mandatory. (Agreement 73.9%, neither 21.7%, disagree 4.3%)
If a patient presents with symptoms of heartburn or regurgitation that have been present for <5 years and has no alarm symptoms (dysphagia, 
weight loss, or anemia), then the patient should be treated medically without further diagnostic testing. (Agreement 60.9%, neither 8.7%, 
disagree 30.4%)
Patients with a family history (2 or more first-degree relatives with BE or EAC) should be considered for endoscopic screening regardless of 
whether or not they have a history of reflux symptoms. (Agreement 69.5%, neither 21.7%, disagree 8.7%)
In patients with BE, all cases of possible dysplasia (indefinite, low grade, high grade) should be reviewed by at least 2 additional pathologists 
with specific expertise in Barrett’s pathology. (Agreement 60.8%, neither 8.7%, disagree 26.1%, strongly disagree 4.3%)
A patient with a columnar-lined distal esophagus without confirmed intestinal metaplasia on biopsy requires at least one follow-up endoscopy. 
(Agreement 65.2%, neither 26.1%, disagree 8.7%)
Patients who have BE should be treated with proton pump inhibitors whether or not they have gastroesophageal reflux disease symptoms or 
endoscopic signs of reflux esophagitis. (Agreement 73.9%, neither 8.7%, disagree 17.4%)
Gastroenterology. Author manuscript; available in PMC 2016 April 04.
